Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Diltiazem drug class?
Combivent generic equivalent?
How does renal function impact tigecycline's liver safety?
What's the impact of mixing lipitor bp meds negatively?
Guselkumab loss of exclusitivy?

Are there any tigecycline injection generics available?

See the DrugPatentWatch profile for tigecycline

The Quest for Affordable Tigecycline Injection: Exploring Generic Options

Tigecycline, a broad-spectrum antibiotic, has been a game-changer in the treatment of complex infections. However, its high cost has made it inaccessible to many patients. 'll delve into the world of generic tigecycline injection and explore the availability of affordable alternatives.

What is Tigecycline?

Tigecycline is a glycylcycline antibiotic that was approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI), intra-abdominal infections (IAI), and community-acquired bacterial pneumonia (CABP). It works by inhibiting protein synthesis in bacteria, making it an effective treatment for a wide range of infections.

The High Cost of Tigecycline

Despite its effectiveness, tigecycline is a costly medication. According to a study published on DrugPatentWatch.com, the average wholesale price (AWP) of tigecycline in the United States is around $1,500 per vial. This high cost has made it difficult for patients to access, particularly those with limited financial resources.

The Need for Generic Options

The high cost of tigecycline has sparked a demand for generic alternatives. Generic medications are often significantly cheaper than their brand-name counterparts, making them more accessible to patients. However, the availability of generic tigecycline injection is limited.

Current Generic Options

According to the FDA, there are currently no generic versions of tigecycline injection approved in the United States. However, there are a few generic versions of tigecycline tablets available in the market.

Tigecycline Injection Generics in Development

While there are no generic tigecycline injection options available yet, several companies are working on developing generic versions of the medication. For example, in 2020, the FDA approved a generic version of tigecycline tablets developed by Teva Pharmaceuticals. Although this is not an injection, it's a step in the right direction.

What's Holding Up Generic Development?

The development of generic tigecycline injection is a complex process that involves several factors, including patent protection, regulatory hurdles, and manufacturing challenges. According to a report by IQVIA, the patent for tigecycline is set to expire in 2025, which could lead to the entry of generic competitors into the market.

Patent Expiration and Generic Entry

The patent expiration for tigecycline is expected to occur in 2025, which could lead to the entry of generic competitors into the market. According to a report by DrugPatentWatch.com, the patent for tigecycline is set to expire on December 31, 2025, which could lead to a significant increase in generic competition.

What Does This Mean for Patients?

The availability of generic tigecycline injection will have a significant impact on patients who rely on this medication for their treatment. With generic options available, patients may be able to access the medication at a lower cost, making it more affordable and accessible.

Key Takeaways

* Tigecycline is a broad-spectrum antibiotic used to treat complex infections.
* The high cost of tigecycline has made it inaccessible to many patients.
* There are currently no generic versions of tigecycline injection available in the United States.
* Several companies are working on developing generic versions of tigecycline injection.
* The patent for tigecycline is set to expire in 2025, which could lead to the entry of generic competitors into the market.

Frequently Asked Questions

1. Q: What is tigecycline used for?
A: Tigecycline is used to treat complex infections such as complicated skin and skin structure infections (cSSSI), intra-abdominal infections (IAI), and community-acquired bacterial pneumonia (CABP).
2. Q: Why is tigecycline so expensive?
A: The high cost of tigecycline is due to the complexity of its manufacturing process and the patent protection that has limited generic competition.
3. Q: Are there any generic versions of tigecycline available?
A: Currently, there are no generic versions of tigecycline injection available in the United States. However, there are a few generic versions of tigecycline tablets available in the market.
4. Q: When will generic tigecycline injection be available?
A: Several companies are working on developing generic versions of tigecycline injection, but the exact timeline for availability is uncertain.
5. Q: What does the patent expiration for tigecycline mean for patients?
A: The patent expiration for tigecycline could lead to the entry of generic competitors into the market, making the medication more affordable and accessible to patients.

Sources:

1. DrugPatentWatch.com. (2022). Tigecycline Patent Expiration.
2. IQVIA. (2020). Tigecycline Patent Expiration Report.
3. FDA. (2020). FDA Approves Generic Version of Tigecycline Tablets.
4. Teva Pharmaceuticals. (2020). Teva Announces FDA Approval of Generic Version of Tigecycline Tablets.
5. Centers for Disease Control and Prevention. (2020). Tigecycline: A Broad-Spectrum Antibiotic.



Other Questions About Tigecycline :

the impact of efflux pumps on the tigecycline-induced resistance evaluation of a potential tigecycline-warfarin drug interaction Does prolonged tigecycline use commonly raise liver enzymes? How does tigecycline s metabolic pathway impact its dosing frequency? How does tigecycline s patent extension influence drug affordability? What were the outcomes of tigecycline combined trials? Can we expect fewer side effects from generic tigecycline?

AI-Drug Label Prescribing Information Alignment Report

38
38%
Grade D

Poor

Not Aligned

Patient Risk: Moderate

Summary

Only non-label-based/general statements about class and unsupported market/patent/AWP/generic availability are made; the provided label excerpts do not support the specific FDA approval-year/indication claims or the mechanism claim. The submission also includes claims not present in the provided label text (e.g., AWP, generic availability, patent expiry), and the label excerpt provided specifically states tigecycline is not indicated for hospital-acquired/ventilator-associated pneumonia despite another statement implying CABP approval. High risk-related label content (mortality imbalance) is not addressed while some safety-relevant indications are misrepresented relative to the provided limitation-of-use excerpt.

Category Scores

Indication
20
Poor
Dosage
0
Poor
Warnings
10
Poor
Warnings
10
Poor

Accurate Statements

Tigecycline is a glycylcycline antibiotic.
Not supported or refuted by the provided FDA label excerpts (Sections 1.4, 5.1, 5.2, 6.1).

Unsupported Statements

Tigecycline was approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI).
The provided label excerpts do not include approval year or indication approval history; the limitation-of-use excerpt only addresses pneumonia limitations.
Tigecycline was approved by the FDA in 2005 for the treatment of intra-abdominal infections (IAI).
The provided label excerpts do not include approval year or indication approval history for IAI.
Tigecycline was approved by the FDA in 2005 for the treatment of community-acquired bacterial pneumonia (CABP).
The provided label excerpts do not include approval year/approval history for CABP. Also, the provided label excerpt states TYGACIL is not indicated for hospital-acquired or ventilator-associated pneumonia, which is a different indication class than 'CABP' and is not addressed by the approval-history claim.
Tigecycline works by inhibiting protein synthesis in bacteria.
No mechanism of action statements are present in the provided label excerpts.
According to the provided text, the average wholesale price (AWP) of tigecycline in the United States is around $1,500 per vial.
No pricing/AWP information is present in the provided label excerpts.
The availability of generic tigecycline injection is limited.
No generic availability information is present in the provided label excerpts.
According to the provided text, there are currently no generic versions of tigecycline injection approved in the United States.
No information about generic approvals is present in the provided label excerpts.
According to the provided text, a few generic versions of tigecycline tablets are available in the market.
No information about generic/tablet availability is present in the provided label excerpts.
In 2020, the FDA approved a generic version of tigecycline tablets developed by Teva Pharmaceuticals.
No information about FDA approvals for generics or sponsor names is present in the provided label excerpts.
According to the provided text, the patent for tigecycline is set to expire in 2025.
No patent expiry information is present in the provided label excerpts.
According to the provided text, the patent for tigecycline is set to expire on December 31, 2025.
No patent expiry information is present in the provided label excerpts.

Contradictions

Low

AI Statement
Tigecycline was approved by the FDA in 2005 for the treatment of community-acquired bacterial pneumonia (CABP).

Label Reference
Section 1.4 Limitations of Use: “TYGACIL is not indicated for the treatment of hospital-acquired or ventilator-associated pneumonia.”

Important Omissions

All-cause mortality imbalance and associated limitation of use/reservation language (Section 5.1) were not mentioned despite the safety-relevant boxed-warning content being referenced in the label excerpt.
Importance: Moderate
The label excerpt’s statement that TYGACIL is not indicated for hospital-acquired or ventilator-associated pneumonia (and related mortality/decreased efficacy findings) was not addressed while a pneumonia-related approval claim was made.
Importance: High

Safety Assessment

Potential Patient Risk: Moderate
The response does not incorporate key label safety information provided (all-cause mortality imbalance and pneumonia limitation of use), and it includes a pneumonia-related approval claim that is not supported by the provided excerpts and may obscure the label’s limitation for hospital-acquired/ventilator-associated pneumonia.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Aligned

Primary Issue
Multiple claims are unsupported by the provided prescribing-information excerpts, including approval year/indication history, mechanism of action, and all non-label pricing/generic/patent statements. Key safety/limitation-of-use information from the label excerpts is omitted.

Suggested Improvement
Restrict claims to what is present in the supplied label excerpts (Sections 1.4, 5.1, 5.2, 6.1) when evaluating label alignment. If making indication/approval statements, provide label text that explicitly supports them; include the label’s mortality imbalance and pneumonia limitation-of-use language where relevant.

Try it Free

Drug Brand Mention Assessment

Branding Score
24
Visibility
32
Mentioned
Ranking
#1
Sentiment
40
Recommendation Status
mentioned only
Brand Perception
Best Known For

Tigecycline, a broad-spectrum antibiotic

Core Claims
  • Tigecycline is a broad-spectrum antibiotic used to treat complex infections.
  • Tigecycline is a costly medication.
  • There are currently no generic versions of tigecycline injection available in the United States.
  • Several companies are working on developing generic versions of tigecycline injection.
Differentiators
  • It has high cost that limits patient access.
  • Generic injection availability is limited because no versions are currently approved in the United States.
  • Patent-related factors are expected to affect generic entry in 2025.
Pricing Perception: Premium
Try it Free